Ophthalmic Toxicities in BEACON Triplet Therapy for BRAF V600E-Mutant Colorectal Cancer: A Case Series
{{output}}
The BEACON regimen, comprising cetuximab, encorafenib, and binimetinib, is a critical treatment for BRAF-mutant metastatic colorectal cancer (mCRC). While effective, this regimen may be associated with a high frequency of serous retinal detachment (SRD) as an ... ...
